LANTHEUS HOLDINGS INC

NASDAQ: LNTH (Lantheus Holdings, Inc.)

最近更新时间: 4天之前, 11:30AM

52.11

-0.90 (-1.70%)

前收盘价格 53.01
收盘价格 52.53
成交量 347,220
平均成交量 (3个月) 1,506,640
市值 3,543,175,424
市盈率 (P/E TTM) 21.62
预期市盈率 (P/E Forward) 9.28
价格/销量 (P/S) 2.43
股市价格/股市净资产 (P/B) 3.14
52周波幅
47.25 (-9%) — 111.29 (113%)
利润日期 6 Nov 2025
营业毛利率 16.55%
营业利益率 (TTM) 27.38%
稀释每股收益 (EPS TTM) 3.51
季度收入增长率 (YOY) 0.80%
季度盈利增长率 (YOY) -44.30%
总债务/股东权益 (D/E MRQ) 52.78%
流动比率 (MRQ) 5.74
营业现金流 (OCF TTM) 525.08 M
杠杆自由现金流 (LFCF TTM) 241.87 M
资产报酬率 (ROA TTM) 14.39%
股东权益报酬率 (ROE TTM) 24.11%

市场趋势

短期 中期
行业 Drug Manufacturers - Specialty & Generic (US) 看涨 混合的
Drug Manufacturers - Specialty & Generic (全球的) 看涨 混合的
股票 Lantheus Holdings, Inc. 看跌 看跌

AIStockmoo 评分

1.3
分析师共识 1.0
内部交易活动 NA
价格波动 4.5
技术平均移动指标 0.0
技术振荡指标 -0.5
平均 1.25

相关股票

股票 市值 DY P/E(TTM) P/B
LNTH 4 B - 21.62 3.14
KNSA 3 B - 89.53 5.72
ALVO 2 B - 22.70 -
BCRX 1 B - - 56.59
HROW 1 B - - 31.74
ETON 514 M - - 18.90

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

部门 Healthcare
行业 Drug Manufacturers - Specialty & Generic
投资方式 Small Growth
内部持股比例 2.24%
机构持股比例 116.12%
52周波幅
47.25 (-9%) — 111.29 (113%)
目标价格波幅
61.00 (17%) — 84.00 (61%)
84.00 (B. Riley Securities, 61.20%) 购买
78.50 (50.64%)
61.00 (Truist Securities, 17.06%) 保留
平均值 75.50 (44.89%)
总计 2 购买, 2 保留
平均价格@调整类型 51.99
公司 日期 目标价格 调整类型 价格@调整类型
Truist Securities 10 Nov 2025 61.00 (17.06%) 保留 50.69
Goldman Sachs 08 Oct 2025 77.00 (47.76%) 保留 53.55
B. Riley Securities 16 Sep 2025 84.00 (61.20%) 购买 51.98
TD Cowen 15 Sep 2025 80.00 (53.52%) 购买 51.74

该时间范围内无数据。

日期 类型 细节
10 Nov 2025 公告 Shareholders SueWallSt in New Class Action Against Lantheus Holdings, Inc. - Act Now
07 Nov 2025 公告 Shareholders SueWallSt in New Class Action Against Lantheus Holdings, Inc. - Act Now
06 Nov 2025 公告 Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update
06 Nov 2025 公告 Lantheus Announces Leadership Transition Plan
04 Nov 2025 公告 Investors SueWallSt as Lantheus Holdings, Inc. Faces Securities Fraud Allegations
03 Nov 2025 公告 INVESTOR DEADLINE NEXT WEEK: RGRD LLP Announces that Lantheus Holdings, Inc. (LNTH) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
31 Oct 2025 公告 Investors SueWallSt as Lantheus Holdings, Inc. Faces Securities Fraud Allegations
30 Oct 2025 公告 Shareholders SueWallSt in New Class Action Against Lantheus Holdings, Inc. - Act Now
30 Oct 2025 公告 Lantheus Announces FDA Grants PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
28 Oct 2025 公告 Lantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer’s Disease
27 Oct 2025 公告 Investors SueWallSt as Lantheus Holdings, Inc. Faces Securities Fraud Allegations
23 Oct 2025 公告 Lantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern Time
22 Oct 2025 公告 Investors SueWallSt as Lantheus Holdings, Inc. Faces Securities Fraud Allegations
16 Oct 2025 公告 Investors SueWallSt as Lantheus Holdings, Inc. Faces Securities Fraud Allegations
14 Oct 2025 公告 LNTH INVESTOR ALERT: Lantheus Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD LLP
09 Oct 2025 公告 Investors SueWallSt as Lantheus Holdings, Inc. Faces Securities Fraud Allegations
06 Oct 2025 公告 Investors SueWallSt as Lantheus Holdings, Inc. Faces Securities Fraud Allegations
24 Sep 2025 公告 Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan
19 Sep 2025 公告 Shareholders SueWallSt in New Class Action Against Lantheus Holdings, Inc. - Act Now
12 Sep 2025 公告 LNTH INVESTOR ALERT: Lantheus Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law
12 Sep 2025 公告 Investors SueWallSt as Lantheus Holdings, Inc. Faces Securities Fraud Allegations
11 Sep 2025 公告 Shareholders SueWallSt in New Class Action Against Lantheus Holdings, Inc. - Act Now
02 Sep 2025 公告 Lantheus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票